- Home
- INSM vs DD Comparison
INSM vs DD Comparison
Compare INSM & DD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- DD
- Stock Information
- Founded
- INSM 1988
- DD 2015
- Country
- INSM United States
- DD United States
- Employees
- INSM N/A
- DD N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- DD Major Chemicals
- Sector
- INSM Health Care
- DD Industrials
- Exchange
- INSM Nasdaq
- DD Nasdaq
- Market Cap
- INSM 29.0B
- DD 32.7B
- IPO Year
- INSM 2000
- DD N/A
- Fundamental
- Price
- INSM $189.60
- DD $81.65
- Analyst Decision
- INSM Strong Buy
- DD Buy
- Analyst Count
- INSM 19
- DD 12
- Target Price
- INSM $171.12
- DD $86.75
- AVG Volume (30 Days)
- INSM 2.1M
- DD 2.9M
- Earning Date
- INSM 10-30-2025
- DD 11-06-2025
- Dividend Yield
- INSM N/A
- DD 2.01%
- EPS Growth
- INSM N/A
- DD N/A
- EPS
- INSM N/A
- DD N/A
- Revenue
- INSM $447,022,000.00
- DD $12,607,000,000.00
- Revenue This Year
- INSM $32.08
- DD $6.77
- Revenue Next Year
- INSM $125.86
- DD $2.62
- P/E Ratio
- INSM N/A
- DD N/A
- Revenue Growth
- INSM 30.34
- DD 4.55
- 52 Week Low
- INSM $60.40
- DD $53.77
- 52 Week High
- INSM $197.08
- DD $87.80
- Technical
- Relative Strength Index (RSI)
- INSM 76.69
- DD 59.07
- Support Level
- INSM $154.79
- DD $80.57
- Resistance Level
- INSM $168.22
- DD $83.40
- Average True Range (ATR)
- INSM 6.44
- DD 1.74
- MACD
- INSM 1.81
- DD 0.11
- Stochastic Oscillator
- INSM 82.31
- DD 80.00
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to spin off its electronics business by the end of 2025, which will be named Qnity. The company also plans to divest its legacy aramid fibers business in early 2026, which contains the Kevlar and Nomex product lines.